Episode 2 of Turning Point is here!.Host @aayshacader speaks with @rallamee about her path from clinician to pioneering researcher. From early grant struggles to leading the ORBITA trial, discover how resilience, courage & teamwork shaped her career.

"The ALL-RISE trial will provide prospective clinical outcomes data on the relative safety, efficacy, and cost-effectiveness of a workflow using FFRangio as compared with pressure wire-based approaches for coronary lesion assessment among patients being considered for

Be sure to downlaod our app and tune in now!

RT @didier_tchetche: RioValves : still time to register! Sept 11-12 🔥🔥.#PCRRioValves.@PCRonline

TAVI in pure aortic regurgitation remains difficult due to limited anchoring forces and the shortcomings of oversizing strategies. The AURORA trial introduced an anatomical classification and dual-anchoring theory, achieving high device success, no procedural mortality, and a low

SESAME, a novel transcatheter septal reduction technique, showed 100% technical success in 54 pts (47 pre-TMVR, 6 oHCM, 1 subaortic membrane). Significant LVOT gradient reduction, improved safety after early learning curve.

A rare OCT finding captured after acetylcholine-induced spasm, resolving with nitroglycerine. @teresabastante.📖 Read the full case here 👇

In this randomised trial of ACS patients with non-culprit lesions, intensive lipid-lowering therapy led to significant plaque lipid regression within 12 weeks. However, adding PCSK9 inhibition offered no further short-term benefit, and plaque volume and physiology remained

🔥 20% back if you lose.First deposit? We’ve got your back. is The Number 1 Solana lootbox site.

In patients with angina and non-obstructive CAD, structural #CMD showed true tissue-level hyperaemic flow restriction independent of subtended myocardial mass, whereas functional CMD does not impair hyperaemic flow once mass is considered. #Cardiology #Microcirculation

EXPLORE THE NEW ISSUE OUT TODAY.✅ Cardiogenic shock in women;.✅ PCSK9 inhibitors and non-culprit lesions;.✅ Coronary microvascular dysfunction;.✅ Residual shunt after PFO closure;.✅ The SESAME technique;.✅ TAVI in pure aortic regurgitation;.✅ Design of the ALL-RISE

The REDUCER-I study showed most patients treated with the coronary sinus Reducer feel better at 1 year, with 99% procedural success and low complication rates. But questions remain: how does it work, and who benefits most?.👉 Read the editorial by @rallamee and M.J. Foley

This study on #PFO closure in elderly patients showed a low rate of cerebrovascular events (CVE) and new-onset AF post-procedure. However, diabetes, atrial septal aneurysm, and advanced age increase CVE risk. #cardiotwitter #EIJBestOf.

This study compared simplified vs. conventional antithrombotic regimens after LAAO in high bleeding risk patients. Results suggest simplified treatment may be as effective with a lower risk of major bleeding, especially for those with prior bleeding. #Cardiology #LAAO #EIJBestOf

M-TEER may benefit selected patients with moderate SMR, not just severe cases. 🫀 1-year registry data show sustained MR reduction, better QoL & fewer HF hospitalisations. Early intervention could prevent HF progression — RCTs needed. #TEER

Zohran Mamdani: He votes for activists, not you

A CT-based assessment of mitral annular calcification (MAC) revealed that leaflet involvement and calcium thickness >5 mm are independent predictors of mortality and heart failure hospitalization following TEER. #TEER #StructuralHeart #Cardiology

The 1-year results of the TriCLASP study support the safety and effectiveness of transcatheter edge-to-edge repair with the PASCAL system in patients with ≥severe tricuspid regurgitation, demonstrating meaningful clinical, functional, and quality-of-life improvements.

RT @PCRonline: My Toolkit 🧰⚙️🔧: Remove the shaft technique. 🔗 When a rota burr stalls in a calcified artery, quick….

RT @AsiaInterv: 🫀#SupraflexCruzDES: 3.1% TLF @ 1 yr in real-world PCI. ✅#Ultrathinstruts. ✅Low thrombosis. 📉Imaging still key to success.Ar….

1-year outcomes from the MiCLASP study: M-TEER with the PASCAL system appeared safe and effective in selected patients with symptomatic moderate FMR, achieving sustained MR reduction, functional improvement, and low adverse event rates. @PhilippLurz, @j_hausleite

Device embolisation after LAAC remains rare (~0.1%) but potentially life-threatening. This paper presents expert consensus from the European LAAC Club on diagnosis, retrieval strategies, and cath lab preparedness. @KeferJoelle .#LAAC #Cardiology #StrokePrevention

RT @PardonMyTake: Tuesday night max woke Big Cat up with a flashlight at 2am because he thought we were going to get sued. @forthepeople ht….

NEW ISSUE OUT.• Device embolisation during LAA closure.• Mitral annular calcification and outcomes after TEER.• 1-year results from MiCLASP (M-TEER) and TriCLASP (T-TEER).• REDUCER-I study outcomes.• Predictors of TVF post-IVL.